Transplantation of myoblasts to Duchenne muscular dystrophy (DMD) patients
Goal of this study
To treat Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disease due to the absence of a protein called dystrophin. DMD is characterized by progressive muscle degeneration and weakness, and is due to deterioration of muscle cells which are important for body movement. This study will investigate the efficacy of the transplantation of normal muscle cells (myoblasts) in the forearm muscle, which allows the extension of the wrist, in patients with DMD. The strength of muscles will be measured at 3 and 6 months post transplantation.
Who can participate in this study?
Patients who have been diagnosed with Duchenne muscular dystrophy and who are 16 years and older may be eligible to participate in this study. This study accepts men and does not accept healthy volunteers.
Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.
ClinicalTrials.gov Identifier: NCT02196467
To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.